Over the past few years, China has been making major strides in the field of medicine. In just the last year, independent teams have managed to reverse both diabetes and autoimmune diseases.
The drug industry has spent months going along with the Trump administration’s efforts to move manufacturing and investment into the U.S., and to disentangle the U.S. and Chinese economies. A long list of big pharmaceutical firms have committed tens of billions of dollars to factories and research facilities in the U.S.
In the past few months, though, U.S. pharma companies have simultaneously supercharged their interest in China-based biotechs, announcing what are likely to be the biggest deals ever for the rights to experimental medicines invented by Chinese companies

在過去的幾年里,中國在醫(yī)學(xué)領(lǐng)域取得了重大進(jìn)展。僅在去年,多個獨立研究團(tuán)隊就成功逆轉(zhuǎn)了糖尿病和自身免疫性疾病。
制藥行業(yè)幾個月來一直配合特朗普政府的努力,推動將制造和投資遷回美國,并試圖實現(xiàn)美中經(jīng)濟(jì)的“脫鉤”。大量大型制藥公司已承諾向美國的工廠和研發(fā)設(shè)施投資數(shù)百億美元。
然而,在過去幾個月中,美國制藥公司卻同時大幅加大了對中國生物科技公司的興趣,宣布了可能成為史上最大規(guī)模的交易,以獲得由中國公司研發(fā)的實驗性藥物的相關(guān)權(quán)益。